The proline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed
in mammalians, releases X-Pro/Ala dipeptides from the N-terminus of peptides. DPP IV is …

Summary Dipeptidyl peptidase‐4 (DPP‐4) inhibitors are a class of oral antidiabetic drugs
that improve glycaemic control without causing weight gain or increasing hypoglycaemic risk …

Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and
sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile …

Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics.
These drugs have been available on the market for the management of type 2 diabetes …

Background No meta-analysis has holistically analysed and summarised the efficacy and
safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap …

Introduction: Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a class of anti-hyperglycemic
agents with proven efficacy in patients with type 2 diabetes mellitus (T2DM). Areas covered …

Background: Given recent discrepant results from randomized controlled trials (RCTs), we
examined the totality of RCT evidence assessing the association between dipeptidyl …

Diabetes mellitus is an emerging predator and affecting around 422 million adults
worldwide. Higher levels of circulating insulin and increased pressure on the pancreas to …

Dipeptidyl peptidase IV (DPPIV) is an exopeptidase that modulates the function of several
substrates, among which insulin-releasing incretin hormones are the most well known …

Gemigliptin, a potent, selective and long-acting DPP 4 inhibitor was developed by LG Life
Sciences and approved for use in patients with type 2 diabetes mellitus by the Korean Food …